ファイル | |
言語 |
英語
|
属性 |
Original article
|
著者 |
秋田 智后
手塚 綾乃
山下 親正
|
内容記述(抄録等) | The NAD+–sirtuin 1 (SIRT1) pathway is essential for neutrophil differentiation induced by the granulocyte-colony stimulating factor, and thus may contribute to neutropenia observed after cancer chemotherapies. This study aimed to investigate the relationship between neutropenia and indices for the activity of the NAD-SIRT1 pathway, i.e., nicotinamide phosphoribosyltransferase (NAMPT) activity and SIRT1 expression in patients receiving chemotherapy for lung cancer. Blood samples were collected from sixteen patients at the start of chemotherapy, at the nadir, and before the start of the second chemotherapy course. Neutrophil counts, NAMPT activity and SIRT1 expression level were measured. There were no differences observed either in NAMPT activity or in SIRT1 expression level between the cases of grade 3–4 neutropenia and those of grade 0–2 neutropenia though the SIRT1 expression level tended to decrease at the nadir. Further studies are required to elucidate this relationship between post-chemotherapy neutropenia and SIRT1 expression.
|
主題 | chemotherapy
lung cancer
neutropenia
SIRT1 expression
|
掲載誌名 |
Shimane Journal of Medical Science
|
巻 | 38
|
号 | 4
|
開始ページ | 119
|
終了ページ | 125
|
ISSN | 03865959
|
ISSN(Online) | 24332410
|
発行日 | 2021-12
|
NCID | AA00841586
|
DOI | |
DOI(SelfDOI) | |
出版者 | Faculty of Medicine, Shimane University
|
出版者別表記 | 島根大学医学部
|
資料タイプ |
紀要論文
|
ファイル形式 |
PDF
|
権利関係 | Faculty of Medicine, Shimane University
|
権利関係(リンク) | This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. |
著者版/出版社版 |
出版社版
|
部局 |
医学部
|
他の一覧 |